Friday 6 November 2026
Export MEDP’s income statement to Excel — free account
Medpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
653.62
18.64
+2.94%
Follow MEDP
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
34.00 | 30.45 | 29.57 | 35.87 |
+8 more quarters Free account |
P/S ratio |
6.14 | 5.36 | 5.10 | 6.40 | |
P/FCF ratio |
26.12 | 21.11 | 19.21 | 23.76 | |
P/Operating CF |
80.52 | 92.10 | 89.99 | 84.10 | |
P/B ratio |
29.81 | 34.39 | 22.83 | 35.29 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.93 | 5.22 | 4.90 | 6.25 | |
EV/EBITDA |
26.55 | 23.77 | 22.19 | 28.09 | |
EV/Operating CF |
23.30 | 19.30 | 17.75 | 22.17 | |
EV/FCF |
25.23 | 20.56 | 18.45 | 23.19 | |
Quick Ratio |
0.77 | 0.66 | 0.78 | 0.67 | |
Current Ratio |
0.83 | 0.73 | 0.85 | 0.74 | |
Net Debt/EBITDA |
(4.10) | (3.27) | (4.40) | (3.10) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.40 | 1.53 | 1.33 | 1.24 | |
Operating CF/Net income |
1.58 | 1.33 | 1.23 | 1.43 | |
Capex/Depreciation |
(3.06) | (3.56) | (0.99) | (0.64) | |
Interest Coverage |
(30.95) | (29.45) | (27.65) | (41.18) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7.23% | 6.80% | 6.78% | 6.34% | |
Intangible Assets out of Total Assets |
0.30 | 0.34 | 0.33 | 0.35 | |
Share Based Compensation of Revenue |
1.06% | 0.61% | 0.70% | 0.79% | |
Graham Net Nets |
(0.03) | (0.04) | (0.03) | (0.03) | |
Graham Number |
93.00 | 77.62 | 87.67 | 74.88 | |
Earnings Yield |
2.94% | 3.28% | 3.38% | 2.79% | |
Free Cash Flow Yield |
3.83% | 4.74% | 5.21% | 4.21% | |
Revenue per Share |
25.63 | 25.11 | 24.84 | 24.56 | |
Operating CF per Share |
7.75 | 5.75 | 5.34 | 6.68 | |
Capex per Share |
(0.72) | (0.85) | (0.24) | (0.16) | |
Free Cash Flow per Share |
7.03 | 4.90 | 5.10 | 6.52 | |
Cash per Share |
25.24 | 17.84 | 22.95 | 17.23 | |
Shareholders Equity per Share |
20.94 | 15.40 | 21.03 | 15.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.94 | 15.40 | 21.03 | 15.91 | |
Free Cash Flow |
196.44 | 138.10 | 144.97 | 188.12 | |
Working Capital |
(251.10) | (385.14) | (205.96) | (354.12) | |
Capital Expenditures |
(20.16) | (23.91) | (6.81) | (4.54) | |
Net Current Asset Value |
(472.66) | (573.03) | (392.24) | (526.78) | |
EV/EBIT |
27.75 | 24.90 | 23.30 | 29.56 | |
Capex to Sales |
0.03 | 0.03 | 0.01 | 0.01 | |
Price to Operating Income |
28.72 | 25.58 | 24.26 | 30.29 | |
| Other line items | |||||
Average Receivables |
410.34 | 409.86 | 346.40 | 349.26 | |
Average Payables |
35.10 | 40.40 | 47.87 | 30.34 | |
Average Assets |
2,027.80 | 1,814.43 | 2,013.49 | 2,038.17 | |
Average Common Equity |
439.29 | 303.11 | 595.96 | 642.31 |
Columns are period end dates · fundamentals updated 2 Nov 2026